Nebula inks its first pharma partnership with Merck Serono to develop treatment for lung cancer

The consumer genomics space has been rife with concerns about data ownership, usage, privacy, and security. From companies getting hacked to ones profiting from consumer data without notice or compensation, consumers have become more concerned about having their genomes sequenced. This unfortunately...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email Thank you!

Related Research

Is it time for AI for drug discovery as a service?

Case Study | October 25, 2021

Despite the value of AI to the pharmaceutical industry in the drug discovery space, significant barriers to its adoption remain. One of the major barriers lies in developing the relevant AI capabilities to tackle questions around novel target identification, lead identification and optimization, ... Not part of subscription

Pfizer partnering with Alex Therapeutics to develop nicotine-addiction DTx

News Commentary | February 08, 2022

Pfizer has partnered with Stockholm‑based DTx (digital therapeutics) maker Alex Therapeutics to deploy artificial intelligence (AI)‑based digital therapeutics. The Alex DTx platform combines cognitive‑based therapy and acceptance and commitment therapy with AI to offer personalized treatment plans. ... Not part of subscription

Ingredient informatics: Trendspotting's value for distributed CPG companies comes into focus

Case Study | May 13, 2022

The use of artificial intelligence and digital means to uncover connections around food is the purpose and value of ingredient informatics. The technology relies on sourcing large but specific datasets that have a variety of business purposes, but a subset of those companies have developed business ... Not part of subscription